Butyrate regulates E-cadherin transcription, isoform expression and intracellular position in colon cancer cells by Barshishat, M et al.
E-cadherin belongs to a family of transmembrane glycoproteins
that bind neighbouring epithelial cells in a homophilic and Ca2+-
dependent way (Takeichi, 1988, 1991; Behrens et al, 1989). The
COOH domain is located within the cell and interacts with
catenins, actin and other cytoskeletal proteins. The NH2-terminal
domain, located in the extracellular domain, contains the Ca2+-
binding sites essential for cell adhesion and binding specificity.
The intracellular segment of E-cadherin interacts with a-, b-, and
g-catenins, which are related to the cytoskeleton proteins vinculin
and actin. In many tumours, mutation and/or gene deregulation
have been detected in all components of the cadherin–catenin
complex. Any of these disorders, either at the genomic or protein
level, affects the stability of the cadherin–catenin complex, which
is directly evidenced by invasion and malignant progression
(Gubiner, 1996). In colon carcinomas, down-regulation of
E-cadherin expression (Frixen et al, 1991), considered a tumour-
suppressor gene (Takeichi, 1993), or alternatively, elevation of
b-catenin expression in cells bearing a mutant APC molecule, is
oncogenic, because target genes related to tumour progression
seem to be activated by this event (Rubinfeld et al, 1997). The
E-cadherin gene promoter has been sequenced (Behrens et al,
1991) and several specific regions have been identified that
contribute to tissue-specific activity and transcription regulation.
These include a GC-rich region that generates basic epithelial
promoter activity, a palindromic sequence E-pal that potentiates
the activity of the proximal E-cadherin promoter, and a CAAT-box
(Behrens et al, 1991).
Butyrate is a short-chain fatty acid formed in the gastrointestinal
tract of mammals as a result of anaerobic bacterial fermentation
of undigested dietary components, and avidly absorbed by the
colonic epithelium. Although butyrate provides the preferred
oxidative fuel for the normal colonocytes (Velazquez et al, 1996),
neoplastic cell lines have been found to undergo terminal differen-
tiation and/or apoptosis when treated with millimolar concentra-
tions of n-butyrate, similar to the physiological intracolonic
luminal concentrations (McBain et al, 1997). Treatment of
mammalian cells in vitro with millimolar concentrations of
butyrate has pleiotropic effects on cellular physiology, including
changes in the cell membrane, cytoskeleton, the cell cycle and
gene transcription (Hassing et al, 1997; Schwartz et al, 1998).
Butyrate regulates transcription expression of multiple genes and
has several effects on nuclear proteins that could modify gene
expression (Nakano et al, 1997; Archer et al, 1998). The signifi-
cance of these varied molecular effects is not well understood and
differs among the many in vitro cell-line studies (Hassing et al,
1997; McBain et al, 1997; Nakano et al, 1997; Archer et al, 1998;
Cuisset et al, 1998). One hypothesis is that butyrate acts as a
co-factor for regulatory transcription proteins in the nuclei that are
directly involved in gene expression (Hassing et al, 1997).
In the present study, we characterized the transcriptional mech-
anisms by which E-cadherin expression is up-regulated by
butyrate in parental non-metastatic and metastatic cell lines.
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Correspondence to: B SchwartzWe demonstrate that butyrate down-regulates the binding of
nuclear proteins to the promoter sequence of the E-cadherin gene,
resulting in up-regulation of the adhesion protein’s expression.
Furthermore, we report that b-catenin is translocated from the
nuclear to the intercellular junctions following butyrate treatment.
MATERIALS AND METHODS
Cell lines and culture conditions
LS174T is a colon cancer cell line derived from a well-differenti-
ated human colonic adenocarcinoma (Tom et al, 1976). An HM7
cell variant of LS174T was previously selected for its capacity to
produce high amounts of mucin (Kuan et al, 1987), relative to
parental LS174T cells and shown to be highly metastatic in in vivo
(Bresalier et al, 1995) and in vitro systems (Schwartz et al, 1992).
Cells were maintained under a humidified atmosphere, 5% carbon
dioxide, in Dulbecco’s minimal essential medium supplemented
with 10% fetal calf serum, 100 units ml–1 penicillin and 100mg
ml–1 streptomycin sulphate, and grown as undifferentiated multi-
layers under controlled conditions. Cells were treated with 2mM
butyrate for 9 days, as previously described (Schwartz et al,
1995a), to induce terminal differentiation.
All media and supplements were purchased from Beit Haemek
(Biological Industries, Israel); biochemicals were purchased from
Sigma Chemical Co. (St Louis, MO, USA) unless otherwise
specified.
Transmission electron microscopy
Cells were fixed in 2.5% glutaraldehyde in 0.1Mcacodylate
buffer, pH 7.4, for 1h. Fixed cells were removed with a rubber
policeman, post-fixed in 1% OsO4, dehydrated in graded ethanol
solutions, and embedded in Epon. Ultrathin sections were
contrasted with uranyl acetate and lead citrate and examined in a
Jeol Jem 1200 EX II transmission electron microscope (Schwartz
et al, 1995a).
Alkaline phosphatase
Alkaline phosphatase activity was determined in cytosolic prepa-
rations by a standard spectrophotometric method using paranitro-
phenyl-phosphate as the substrate (Schwartz et al, 1995a).
Western blot analysis
Cells were lysed, electrophoresed on a 10% sodium dodecyl
sulphate (SDS) polyacrylamide gel, transferred to a nylon-transfer
membrane (Amersham, Buckinghamshire, UK), blocked in TBS
(10mMTris-base, 100mMsodium chloride) containing 5% dry
non-fat milk, incubated with mouse anti-human E-cadherin mono-
clonal antibody (Transduction Laboratories, Lexington, KY,
USA), or b-catenin polyclonal antibody and subsequently incu-
bated with secondary antibodies coupled to horseradish peroxi-
dase. Both proteins were visualized using an enhanced
chemiluminescence kit (ECL; Amersham, Buckinghamshire, UK).
Immunocytochemistry
Cells were grown on chamber slides. Fixation and abrogation of
endogenous peroxidase activity were performed in a solution of
3% hydrogen peroxide and 95% methanol. The fixed cells were
incubated in an antibody directed to the extracellular domain of
E-cadherin (DECMA-1) or in an anti-E-cadherin antibody directed
to the intracellular domain (Transduction Laboratories, Lexington,
KY, USA). Detection was performed with Vectastain Elit kit
(Vector Laboratories, Burlingame, CA, USA). Counterstaining
was performed with haematoxylin (Schwartz et al, 1995b).
E-cadherin reverse transcription-polymerase chain
reaction
cDNA was synthesized from 5mg of total RNA using a reverse
transcription polymerase chain reaction (RT-PCR) kit (Promega,
Madison, WI, USA). The primers used for the exon-9 sequence
are: 5¢CTCAGCTCTGCTAGCAGTCTTG 3¢(forward), and 5¢
GATGAACACCTGTGAGGAG 3¢(reverse). The PCR amplifica-
tion conditions were: 30s, 94°C; 30s, 55°C; 30s, 72°C, for 30
cycles. PCR products were separated by agarose gel; molecular
weight was confirmed with a 123-bp DNA ladder (Gibco-BRL,
Paisley, UK).
Human serum albumin RT-PCR
cDNA was synthesized from 5mg of total RNA using an RT-PCR
kit (Promega, Madison, WI, USA). The primers used for the
PCR amplification were 5¢CCAAGAAAGTACCCCAAGTGTC
3¢  (forward), and 5¢TGTTTCATCGACTTCCAGAGC 3¢
(reverse). PCR amplification conditions were: one cycle at 94°C
for 2.5min, ten cycles at 40s, 94°C; 30s, 55°C; 20 cycles at 30s,
94°C; 20s, 53°C, 1min, 72°C and then one cycle at 72°C for
5min. PCR products were separated by agarose gel; molecular
weight was confirmed with a 123-bp DNA ladder (Gibco-BRL,
Paisley, UK).
Amplification of E-cadherin promoter by PCR
A 330-bp fragment from the human E-cadherin promoter was
amplified (from 721 to 1080, GenBank database L34545)
(Bussemakers et al, 1994) using primers: upstream 5¢-ACTCAGC-
CAAGTGTAAAAG-3¢, downstream 5¢-TCACAGGTGCTTTG-
CAGTT-3¢. The PCR programme was: 35 cycles of 94°C; 45s,
46°C; 45s, 72°C and one cycle at 72°C for 5min. The PCR prod-
ucts were separated on an agarose gel, their molecular weight
confirmed with a 123-bp DNA ladder, and completely sequenced
to ensure no unexpected mutations.
Gel shift mobility assay
Nuclear proteins were extracted from 5 ´106–107 control or
butyrate-treated cells as previously described (Andrews et al,
1991). Nuclear proteins (10mg) were preincubated with poly
dI-dC and then in reaction buffer (100mMTris–HCl pH 7.9,
25mMmagnesium chloride (MgCl2), 2mMEDTA, 40% glycerol,
200mMpotassium chloride, 0.2% NP-40 and 2mMdithiothreitol,
and the 330-bp amplified DNA fragment of E-cadherin promoter
sequence was end-labelled with [g-32P]ATP and T4 polynucleotide
kinase (BioLab New England, Beverly, MA, USA). The samples
were separated by electrophoresis in a 2.4% acrylamide gel. The
gel was dried and subjected to autoradiography (Carey, 1991).
b-catenin detection by immunofluorescence staining
Cells were grown on coverslips for 9 days with or without
butyrate. The coverslips were rinsed in a phosphate-buffered
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calcium chloride). Fixation was performed with cooled methanol
(–20°C) for 10 min and 1 min in cooled acetone (–20°C). 
The fixed cells were incubated with a human polyclonal anti-b-
catenin antibody. The secondary antibody used was rhodamine-
labelled goat anti-rabbit IgG (Promega, Madison, WI, USA).
Counterstaining was performed with 4¢6-diamidino-2-phenylindole
hydrochloride (DAPI) diluted in anti-fade solution (0.7 mg ml–1).
RESULTS
Characteristics of cell differentiation
We studied the effect of butyrate treatment by means of differenti-
ation-related criteria: ultramorphological analysis and alkaline
phosphatase activity.
Ultrastructurally, LS174T control cells showed scattered signs
of differentiation, sparse brush-border membranes, and minimal
cell-to-cell contacts (Figure 1 A,B). In contrast, butyrate-treated
cells showed well-defined cell-to-cell contacts, well-developed
junctional complexes (Figure 1 C,D) and cells bearing a goblet-
like morphology. The highly metastatic HM7 cells grown under
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Figure 1 (A–D) Representative ultrastructural analysis of LS174T cells. (A, B) Partially differentiated untreated cells, showing undeveloped brush-border
membranes and few contact points between the cells. (C, D) Butyrate-treated LS174T cells, polarized and adhering to each other. Typical signs of differentiation
are observed, e.g. appearance of goblet cells (D). (E–H) Representative ultrastructural analysis of HM7 cells. (E, F) Untreated cells show no intercellular
contacts, and a high nuclei/cytoplasm ratio. Butyrate-treated HM7 cultures (G, H) show well-organized epithelial cells, highly polarized and notable intercellular
contacts are evident, resulting in a tissue-like appearance of this culture
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Figure 2 Alkaline phosphatase activity in LS174T and HM7 cells cultured
for 9 days in control media (CT) (n) is low. Cells incubated in media
containing 2 mM butyrate (NB) ( ) show significant (P < 0.001) enhancement
of alkaline phosphatase activity relative to their respective control cultures.
The values represent the mean ± s.e.m. of six individual determinations198 M Barshishat et al
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Figure 3 (A–F) Immunohistochemical E-cadherin analysis of LS174T and HM7 cells. Cells were stained with extracellular and intracellular E-cadherin-directed
antibodies. (A, B, C) LS174T cells stained with both antibodies. Control cells stain positively for E-cadherin and butyrate accentuates this pattern.
(D) Extracellular staining is not detected in HM7 cells. (E) Intracellular staining of HM7 cells shows expression in the membrane and/or also in the nuclei (see
arrows). (F) Butyrate-treated HM7 cells: E-cadherin is expressed strongly in the extracellular domain. (G) Western blot analysis of E-cadherin protein. Control
(CT) LS174T cells and HM7 cells exhibit the 100- and the 120-kDa isoforms. Butyrate treatment (NB) causes the disappearance of the 100-kDa E-cadherin
species in both cell lines. The effect is more pronounced in HM7 cells. The results represent one representative experiment of four identical performedcontrol conditions were sparse and intracellular junctions were
absent. These cells had a high nucleus/cytoplasm ratio. The
cultures were not polarized and no contact between the cells was
observed (Figure 1 E,F). Following butyrate treatment, striking
morphological changes emerged: the cells showed polarized
morphology and well-defined cell-to-cell contacts, junctional
complexes and brush-border membranes (Figure 1 G,H).
Alkaline phosphatase activity was determined in control
LS174T and HM7 colon cancer cells. Basal activity was higher in
the LS174T cells than in HM7 (Figure 2). Following 9 days of
butyrate treatment, a threefold rise in enzymatic activity was
observed in the LS174T cells relative to their untreated counter-
parts. Although the HM7 cells showed a significant, twofold
increase in enzymatic activity as compared to controls, absolute
values were lower than those of the treated LS174T cells
(Figure 2).
E-cadherin immunocytology
Immunocytochemical staining of the extracellular domain of
E-cadherin in LS174T control cells revealed both diffuse and
typical extracellular organization of protein expression (Figure
3A). Reaction with antibody directed to the intracellular domain of
E-cadherin, the same used for the Western analysis, showed
mostly membrane staining in LS174T control cells, similar to the
extracellular antibody, and minimal nuclear staining (Figure 3B).
Complete translocation of this diffuse and faint nuclear staining to
the extracellular junctions was observed in LS174T cells after
butyrate treatment, as evidenced by immunocytochemical reac-
tions with both antibodies (Figure 3C).
E-cadherin expression in control HM7 cells was sporadic, with
a predominant non-specific staining pattern using antibody to the
extracellular domain, and was evident in small groups of cells
(Figure 3D). A high amount of nuclear staining was detected in
HM7 control cells when antibody directed to the intracellular
domain was used (Figure 3E). In comparison, striking difference
was observed in HM7 cells treated with butyrate. Butyrate-treated
cells showed typical extracellular staining of E-cadherin,
mimicking a delicate net. Similar immunocytochemical results
were obtained with both antibodies. Nuclear staining was not
detected in HM7 cells after butyrate treatment (Figure 3F). Similar
staining patterns were obtained with both the intracellular (data not
shown) and extracellular staining (Figure 3 C,F).
Regulation of E-cadherin expression by butyrate
Figure 3G shows a Western blot analysis of E-cadherin protein
from LS174T and HM7 cells untreated or treated with butyrate,
using antibody directed to the intracellular domain of the protein.
Untreated LS174T and HM7 cells showed full-size (120 kDa) and
a smaller size (100 kDa) E-cadherin reactive protein. The expres-
sion of the low-molecular-weight isoform was higher in the
aggressive HM7 cells than in the LS174T parental cells. Butyrate
treatment up-regulated the expression of the 120-kDa isoform and
completely abolished that of the 100-kDa isoform. This effect was
more pronounced in HM7 cells than in the parental LS174T cells.
RNA expression detected by RT-PCR
The expression of E-cadherin was analysed by RT-PCR (Figure
4A). Although the methodology is semi-quantitative, the level of
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Figure 4 RT-PCR assay to analyse the expression of: (A) E-cadherin
cDNA 123-bp products. RNA was harvested from LS174T and HM7 cells,
untreated (CT) or treated with butyrate (NB). Butyrate induced significant
up-regulation of E-cadherin expression in both cell lines. M: 123-bp marker.
(B) The housekeeping gene human serum albumin, to ensure equal RNA
loading. The figure is one representative experiment out of four performed
Figure 5 (A) A gel mobility assay was carried out with nuclear extracts from
butyrate-treated (NB) or untreated (CT) colon cancer cells. A 123-bp
sequence of exon-9 was used as a control specific-binding experiment.
Similar results were obtained in eight additional experiments. (B) The 330-bp
E-cadherin promoter sequence containing the E-pal palindromic element
(bold), the CAAT-box (italic) and Sp1 consensus sequence (underlined) was
g-32P end-labelled and used for the gel mobility assayexpression could be clearly established because transcription of
the E-cadherin gene was significantly up-regulated in the presence
of butyrate in HM7 cell cultures. This was also the case for
butyrate-treated LS174T cells. To ensure that closely matched
amount of cDNA from RNA were used in the reaction a portion of
the housekeeping gene HSA was amplified in parallel with the
E-cadherin primers. Equal amounts of HSA were detected in both
cell lines with ore without butyrate treatment (Fig 4B).
Gel mobility assay
The ability of nuclear proteins to bind to a 330-bp segment of
human E-cadherin promoter and to the 123-bp sequence of exon 9
was assessed (Figure 5). Nuclear proteins did not bind to exon 9.
The highest binding activity of nuclear proteins to the E-cadherin
promoter was detected when the extract was derived from HM7
control cells. This binding capacity was abrogated by butyrate
treatment. LS174T cells showed a similar pattern of binding
activity following butyrate treatment; however, its overall inten-
sity was lower as compared to HM7 cells.
b-catenin translocation after butyrate treatment
b-catenin was detected in both untreated LS174T cells (not
shown) and HM7 cells (Figure 6). In LS174T cells, butyrate treat-
ment did not affect b-catenin immunostaining. In control HM7
cells, b-catenin was sporadic; a non-specific intracellular staining
pattern was predominant and several b-catenin immunoresponsive
spots were detected within the nuclei (Figure 6A, see arrows).
However, when HM7 cells were treated with butyrate, dramatic
translocation of b-catenin out of the nucleus took place and strong
typical intercellular junctional staining was evident (Figure 6B).
Western blot analysis revealed that the level of b-catenin expres-
sion is not affected by butyrate treatment in either LS174T or HM7
cells (Figure 6C).
DISCUSSION
We studied two colon cancer cell lines differing in a number of
phenotypes: (i) a parental colon cancer cell line (LS174T) charac-
terized by its low capacity to produce mucin concomitant with its
low ability to colonize the liver in experimental animal models,
and (ii) a high-mucin selected clone (HM7) characterized by high
in vivo and in vitro invasive characteristics (Schwartz et al, 1992;
Bresalier et al, 1995). Ultramorphological analysis of both cultures
reveal that LS174T cells show scattered signs of differentiation
and intercellular contacts and HM7 cells without any sign of inter-
cellular contact.
Alkaline phosphatase activity is considered to be a valid marker
of colonic differentiation (Schory et al, 1994; Schwartz et al,
1995a). Consistent with this view, the lowest alkaline phosphatase
activity was measured in the untreated, undifferentiated HM7
cells. Higher levels were observed in partially differentiated
LS174T cells. We then compared the responses of the two colon
cancer cell lines to butyrate treatment. In both cultures, intercel-
lular contacts were enhanced after the treatment. Ultrastructurally,
the invasive clone responded more strongly to butyrate treatment.
The intercellular adhesive capacity, particularly in HM7 cells,
changed dramatically. Butyrate-treated HM7 cells showed a polar-
ized morphology, brush-border structures typical to differentiated
colonocytes, differentiated goblet cells and, most significantly, the
appearance of many tight connections between the cells.
Takeichi (1993) reported that decreased expression of
E-cadherin is correlated with de-differentiation and metastasis in
200 M Barshishat et al
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Figure 6 Representative immunofluorescent staining (A, B) and Western blot analysis (C) for the detection of b-catenin using a polyclonal anti-b-catenin
antibody. (A) Control HM7 cells show sporadic and non-specific intracellular staining; significant nuclear expression is evident (see arrows). (B) HM7 cells
treated with butyrate: b-catenin staining is evident exclusively at the intercellular borders. No immunofluorescent staining is detectable within the nuclei. Similar
findings were obtained for control and butyrate-treated LS174T cells (data not shown). (C) b-catenin expression was not affected by butyrate treatment as
detected by Western blot analysis. The same was found for LS174T cellsseveral poorly differentiated carcinomas. Mutation or transcrip-
tional down-regulation are major mechanisms leading to decreased
E-cadherin expression (Becker et al, 1994; Henning et al, 1995).
The cell-adhesion molecule E-cadherin is a 120-kDa cell-surface
glycoprotein, from which an intracellular cytosolic 100-kDa
soluble fragment can be released (Gofuku et al, 1998). The
parental LS174T cells and the highly invasive HM7 subclone
expressed both the full-size and the intracellular cytosolic tryptic
100-kDa soluble protein isoform. Treatment of both cell types with
butyrate induced the disappearance of the 100-kDa isoform and
up-regulation of the 120-kDa full-size protein. The extent of the
up-regulation response differed between the parental LS174T cells
and the highly invasive HM7 subclone with butyrate treatment
inducing a higher up-regulation of E-cadherin in HM7 cells. It can
be surmised that the parental, less aggressive LS174T cell lines are
in a more advanced stage of differentiation, which is merely accen-
tuated by the treatment.
We performed an immunohistochemical analysis with two
different antibodies to E-cadherin, directed to the intracellular or
the extracellular domain. Extracellular staining showed a signifi-
cant amount of the E-cadherin expression in untreated LS174T
cells to be confined to the intercellular junctions; butyrate treat-
ment only emphasized this pattern. The expression of E-cadherin
was sporadic, faint and diffuse in control HM7 cells. In contrast,
butyrate-treated HM7 cells showed the typical extracellular
staining of E-cadherin, resembling a delicate net, and increased
levels of E-cadherin expression accompanied by a clear intercel-
lular redistribution of the protein. The intracellular staining
showed E-cadherin expression in untreated LS174T cells to be
confined to the intercellular junctions, with little localization in the
nuclei, whereas in HM7 cells, E-cadherin was sporadic, faint,
diffuse and mostly localized in the nuclei. These findings suggest
that the increased contact between butyrate-treated LS174T and
HM7 cells is associated with the enhanced E-cadherin expression.
To understand the mechanism by which butyrate up-regulates
E-cadherin expression, we first investigated the possibility that
treatment of the cells with the short fatty acid causes selection for
a cell subpopulation presenting the normal E-cadherin gene. We
assumed that the non-treated cultures contained some cells
expressing the normal adhesion protein gene and some bearing the
putative mutation lacking a G nucleotide at the exon/intron
9 border of the E-cadherin gene known to encode the calcium-
binding site (Becker et al, 1994). Analysis of this possible specific
and common mutation by nested PCR methodology revealed that
butyrate does not select a mutant-free cell culture (data not
shown).
Another approach was to search for events, which do not
involve irreversible genetic alterations. Increased transcriptional
activity is a major mechanism leading to increased protein expres-
sion (Bussemakers et al, 1994). We have shown that butyrate treat-
ment of LS174T parental cell lines and HM7 cells specifically
induces E-cadherin mRNA and protein. The human E-cadherin
gene promoter comprises regulatory regions composed of various
consensus sequences known as cis-acting elements, such as E-pal,
the CAAT-box and a GC-rich region (Figure 6B), that contribute
positively or negatively to promoter activity (Walsh and Doherty,
1993). We amplified a 330-bp segment of the promoter, including
all the aforementioned consensus sequences and identified cell-
specific band-retardation shifts within this sequence. The binding
of the nuclear proteins was most notable in control HM7 cells, less
pronounced in control LS174T cells, and significantly reduced in
butyrate-treated LS174T and HM7 cells. Sequential control exper-
iments not including cis-acting elements (exon-9) did not exhibit
similar binding of nuclear proteins, indicating specificity of the
promoter region analysed. These findings suggest that the
enhanced binding of nuclear proteins to the 330-bp promoter
region in LS174T and HM7 cells is associated with transcriptional
repression of the E-cadherin gene. Butyrate may induce displace-
ment of those nuclear proteins that bear repressor activity. Henning
et al (1995) demonstrated that loss of differentiation of a wide
range of carcinoma cells, as revealed by down-regulation of
E-cadherin expression, directly correlates with specific changes in
the chromatin structure. They observed that in undifferentiated
cells, chromatin acquires a more condensed conformation,
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Figure 7 Hypothetical mechanism of action of butyrate on HM7 colon cancer cells. (A) Control conditions, (B) effect of butyratepreventing the free approach of transcription factors to essential
elements within the promoter. Upon butyrate treatment, global
modification of chromatin proteins, such as hyperacetylation of
histones, may result in significant interactions with these regula-
tory regions, enabling constitutively expressed, general transcrip-
tion factors to gain access to their recognition sequences, recruit
other factors, and activate transcription by direct activation or
depression. In this study, we show that E-cadherin gene expression
is up-regulated by butyrate treatment and that the short-chain fatty
acid interacts with nuclear proteins which ultimately allow gene
transcription and enhanced protein expression.
We show that b-catenin is differentially compartmentalized in
the different cell lines, both in controls and after butyrate treat-
ment. b-catenin, localized to the nuclei of control cells, was more
evident in the high-mucin (HM7) cell line than in the parental one
(LS174T). Butyrate induced dramatic translocation of b-catenin
from the nuclei into the intercellular junctional domain in both cell
lines. Treatment with the short-chain fatty acid did not, however,
affect intracellular b-catenin protein concentration. The presence
of nuclear b-catenin may indicate that the protein, by itself or in
association with lymphoid-enhancing binding factors family
(LEF/TCF), can transcriptionally regulate gene activity (Simcha
et al, 1998a). Alternatively, transmembrane localization of
b-catenin, due to strong binding to E-cadherin rather than to LEF,
may result in inhibited transactivation activity and the oncogenic
nature of the adhesion protein (Simcha et al, 1998a).
The mechanism by which butyrate induces the specific translo-
cation of b-catenin from the nucleus to the transmembranal
domain has yet to be elucidated; however, it may be related to the
presence of the 100-kDa cytoplasmatic domain of E-cadherin in
the untreated cell lines. Simcha et al (1998b) showed that transfec-
tion with the cytoplasmic tail of E-cadherin inhibits transactivation
by competing with LEF-1 in the nucleus for b-catenin binding.
Their results indicate that the cytoplasmic partners of b-catenin,
E-cadherin and a-catenin, can sequester b-catenin and inhibit its
transcriptional activity, thereby antagonizing its oncogenic action.
We assume that this cytoplasm E-cadherin isoform is able to
bind b-catenin as do the LEF/TCF nuclear transcription factors.
Once this complex is obtained, the 100-kDa protein may act as a
nuclear protein allowing the translocation of b-catenin to the
nuclei and subsequently regulate the expression of cancer-related
genes. Butyrate treatment induced the total abrogation of 100-kDa
E-cadherin expression concomitant with significant up-regulation
of the 120-kDa full-size glycoprotein’s expression. Therefore, in
treated cells, b-catenin does not have its ‘nuclear translocating
partner’, i.e. the 100-kDa E-cadherin isoform. On the contrary,
there is enhanced expression of the transmembranal protein that
sequesters b-catenin to the membranous domain (see a scheme of
our hypothesis in Figure 7A and B). In the cell lines studied, the
varying extent of b-catenin nuclear translocation could result from
quantitative differences in 100-kDa E-cadherin expression. Both
cell lines differ in mucin content and express MUC1 (unpublished
results). Li et al (1998) demonstrated that the cytoplasmic domain
of MUC1 interacts with b-catenin. The higher the expression of
the MUC1 glycoprotein, the lower the interaction of b-catenin
with the E-cadherin cell-adhesion molecule, allowing free
b-catenin to reach the nuclei. It would appear that in high-mucin-
producing cell lines, less b-catenin molecules interact with the
120-kDa transmembranal E-cadherin and are thus free to be
translocated into the nucleus. In the low-mucin-producing cells,
lower numbers of b-catenin molecules reach the nucleus.
Cumulatively, our findings suggest that treatment with specific
substances, such as butyrate, can convert a passive essential
promoter of a tumour-suppressor gene, such as the E-cadherin
promoter, to an active form, thereby affecting the entire metastatic
process. Studies showing these direct effects are in progress in our
laboratory.
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